108 related articles for article (PubMed ID: 1407246)
1. Parkinson's disease in Taiwan: an analysis of 215 patients.
Chia LG; Liu LH
Neuroepidemiology; 1992; 11(3):113-20. PubMed ID: 1407246
[TBL] [Abstract][Full Text] [Related]
2. Prognosis of Parkinson's disease: time to stage III, IV, V, and to motor fluctuations.
Sato K; Hatano T; Yamashiro K; Kagohashi M; Nishioka K; Izawa N; Mochizuki H; Hattori N; Mori H; Mizuno Y;
Mov Disord; 2006 Sep; 21(9):1384-95. PubMed ID: 16763980
[TBL] [Abstract][Full Text] [Related]
3. [Progress in the basic and clinical aspects of Parkinson's disease].
Mizuno Y
Rinsho Shinkeigaku; 2004 Nov; 44(11):741-50. PubMed ID: 15651281
[TBL] [Abstract][Full Text] [Related]
4. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
Jost WH; Klasser M; Reichmann H
Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up of early dopa treatment in Parkinson's disease.
Markham CH; Diamond SG
Ann Neurol; 1986 Apr; 19(4):365-72. PubMed ID: 3707088
[TBL] [Abstract][Full Text] [Related]
6. Differential progression of motor impairment in levodopa-treated Parkinson's disease.
Goetz CG; Stebbins GT; Blasucci LM
Mov Disord; 2000 May; 15(3):479-84. PubMed ID: 10830412
[TBL] [Abstract][Full Text] [Related]
7. Clinical course of patients with idiopathic Parkinson's disease.
Roos RA; Jongen JC; van der Velde EA
Mov Disord; 1996 May; 11(3):236-42. PubMed ID: 8723138
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
[TBL] [Abstract][Full Text] [Related]
9. Parkinsonism treated with levodopa: progression and mortality.
Maier Hoehn MM
J Neural Transm Suppl; 1983; 19():253-64. PubMed ID: 6583311
[TBL] [Abstract][Full Text] [Related]
10. Plasma homocysteine level and its relationship to clinical profile in Parkinson's disease patients at the Lagos University Teaching Hospital.
Ojo OO; Oladipo OO; Ojini FI; Sanya EO; Danesi MA; Okubadejo NU
West Afr J Med; 2011; 30(5):319-24. PubMed ID: 22752818
[TBL] [Abstract][Full Text] [Related]
11. Mortality associated with early and late levodopa therapy initiation in Parkinson's disease.
Scigliano G; Musicco M; Soliveri P; Piccolo I; Girotti F; Giovannini P; Caraceni T
Neurology; 1990 Feb; 40(2):265-9. PubMed ID: 2300246
[TBL] [Abstract][Full Text] [Related]
12. Levodopa therapy and survival in idiopathic Parkinson's disease: Olmsted County project.
Uitti RJ; Ahlskog JE; Maraganore DM; Muenter MD; Atkinson EJ; Cha RH; O'Brien PC
Neurology; 1993 Oct; 43(10):1918-26. PubMed ID: 8413948
[TBL] [Abstract][Full Text] [Related]
13. Clinical phenotype and risk of levodopa-induced dyskinesia in Parkinson's disease.
Nicoletti A; Mostile G; Nicoletti G; Arabia G; Iliceto G; Lamberti P; Marconi R; Morgante L; Barone P; Quattrone A; Zappia M
J Neurol; 2016 May; 263(5):888-894. PubMed ID: 26964541
[TBL] [Abstract][Full Text] [Related]
14. [The use of antiparkinsonism drugs in 92 cases in Xi'an city].
Zhe X; Qu QM; Wang RL; Cao HM; Qiao J; Guo F
Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Oct; 30(10):1065-8. PubMed ID: 20193391
[TBL] [Abstract][Full Text] [Related]
15. Parkinson's disease: progression and mortality.
Hoehn MM
Adv Neurol; 1987; 45():457-61. PubMed ID: 3825726
[TBL] [Abstract][Full Text] [Related]
16. [Motor levodopa-induced complications in Parkinson's disease].
Michałowska M; Fiszer U; Szatanowski T
Pol Merkur Lekarski; 2016 Jun; 40(240):357-61. PubMed ID: 27403901
[TBL] [Abstract][Full Text] [Related]
17. Subthalamic nucleus stimulation for Parkinson disease: benefits observed in levodopa-intolerant patients.
Katayama Y; Kasai M; Oshima H; Fukaya C; Yamamoto T; Ogawa K; Mizutani T
J Neurosurg; 2001 Aug; 95(2):213-21. PubMed ID: 11780890
[TBL] [Abstract][Full Text] [Related]
18. Efficiency and safety of bilateral contemporaneous pallidal stimulation (deep brain stimulation) in levodopa-responsive patients with Parkinson's disease with severe motor fluctuations: a 2-year follow-up review.
Ghika J; Villemure JG; Fankhauser H; Favre J; Assal G; Ghika-Schmid F
J Neurosurg; 1998 Nov; 89(5):713-8. PubMed ID: 9817406
[TBL] [Abstract][Full Text] [Related]
19. Profile of levodopa-induced dyskinesia in patients of Parkinson's disease: a record based study.
Choudhury S; Pradhan R; Paul P; Das M; Gupta A; Ghosh P; Chatterjee S
Neurol Res; 2014 Sep; 36(9):841-6. PubMed ID: 24601722
[TBL] [Abstract][Full Text] [Related]
20. The impact of treatment with levodopa on Parkinson's disease.
Shaw KM; Lees AJ; Stern GM
Q J Med; 1980; 49(195):283-93. PubMed ID: 7465763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
